
AnPac Bio-Medical Science Co., Ltd. ANPC
Annual report 2022
added 12-27-2025
AnPac Bio-Medical Science Co., Ltd. Interest Expense 2011-2026 | ANPC
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense AnPac Bio-Medical Science Co., Ltd.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 236 K | 238 K | 728 K | 2.61 M | 925 K | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.61 M | 236 K | 947 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
685 K | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Ascendis Pharma A/S
ASND
|
80.6 M | $ 215.54 | -1.16 % | $ 5 B | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Aquestive Therapeutics
AQST
|
6.55 M | $ 3.88 | -1.27 % | $ 415 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 19.23 | - | $ 899 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
1.24 M | $ 8.18 | -2.97 % | $ 109 M | ||
|
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
16.4 M | - | - | $ 546 M | ||
|
Cara Therapeutics
CARA
|
3.59 M | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
9.29 M | $ 1.32 | -5.71 % | $ 337 M | ||
|
CytomX Therapeutics
CTMX
|
28 K | $ 4.24 | -4.83 % | $ 585 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
52 K | - | -5.98 % | $ 34.1 M | ||
|
ChemoCentryx
CCXI
|
2.7 M | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.65 | 0.76 % | $ 16.6 M | ||
|
Dynavax Technologies Corporation
DVAX
|
293 K | - | - | $ 2.02 B | ||
|
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | ||
|
Enochian Biosciences
ENOB
|
122 K | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Eton Pharmaceuticals
ETON
|
955 K | $ 22.97 | -3.53 % | $ 618 M | ||
|
Exelixis
EXEL
|
-198 K | $ 41.57 | 0.39 % | $ 11.3 B | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Fortress Biotech
FBIO
|
1.32 M | $ 2.92 | -2.01 % | $ 60.7 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
459 K | $ 4.31 | -2.49 % | $ 826 M | ||
|
Homology Medicines
FIXX
|
1.18 M | - | 0.77 % | $ 53.4 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M |